Unique ID issued by UMIN | UMIN000036930 |
---|---|
Receipt number | R000042088 |
Scientific Title | Ovidrel Syringe 250 microgram Drug Use-Results Survey |
Date of disclosure of the study information | 2019/06/04 |
Last modified on | 2023/09/13 08:38:26 |
Ovidrel Syringe 250 microgram Drug Use-Results Survey
Drug Use-Results Survey of Ovidrel
Ovidrel Syringe 250 microgram Drug Use-Results Survey
Drug Use-Results Survey of Ovidrel
Japan |
- Ovulation induction and luteinization in infertile patients with oligo- or anovulation due to a dysfunction in hypothalamic-pituitary system
- Final follicle maturation and early luteinization in Assisted Reproductive Technologies
Obstetrics and Gynecology |
Others
NO
To investigate safety and efficacy of Ovidrel in clinical practice
Safety,Efficacy
The incidence of adverse drug reactions and infections, the incidence of serious adverse events, and so on
Observational
Not applicable |
Not applicable |
Female
For the indications of Ovidrel, which are ovulation induction and luteinization in anovulation or oligoovulation associated with hypothalamic-pituitary dysfunction and maturation of ovum and luteinization in assisted reproductive technology, patients who receive Ovidrel for the first time and give consent to participation in this survey.
For self-injection at home, patients who received Ovidrel for the first time through self-injection at home.
Patients with contraindications in the package insert.
320
1st name | Hidehiko |
Middle name | |
Last name | Momo |
Merck Biopharma Co., Ltd.
PMS Planning & Strategy, Medical Department
153-8926
Arco Tower 4F, 8-1, Shimomeguro 1-chome, Meguro-ku, Tokyo, Japan
03-6756-0791
hidehiko.momo@merckgroup.com
1st name | Tatsuya |
Middle name | |
Last name | Ogura |
Merck Biopharma Co., Ltd.
PMS Planning & Strategy, Medical Department
153-8926
Arco Tower 4F, 8-1, Shimomeguro 1-chome, Meguro-ku, Tokyo, Japan
03-6756-0750
tatsuya.ogura@merckgroup.com
Merck Biopharma Co., Ltd.
Merck Biopharma Co., Ltd.
Profit organization
Merck Biopharma Co., Ltd.
Arco Tower 4F, 8-1, Shimomeguro 1-chome, Meguro-ku, Tokyo, Japan
03-6756-0750
tatsuya.ogura@merckgroup.com
NO
2019 | Year | 06 | Month | 04 | Day |
Unpublished
419
Completed
2017 | Year | 08 | Month | 24 | Day |
2017 | Year | 08 | Month | 24 | Day |
2017 | Year | 09 | Month | 25 | Day |
2020 | Year | 03 | Month | 31 | Day |
Drug Use-Results Survey according to the GPSP ordinance
2019 | Year | 06 | Month | 03 | Day |
2023 | Year | 09 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042088
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |